New hope for High-Risk blood cancer patients in transplant trial
NCT ID NCT07228624
Summary
This study is testing if adding a drug called ruxolitinib to standard treatment can make stem cell transplants safer and more effective for older adults with myelofibrosis or related blood cancers. The main goal is to prevent a dangerous complication where the donor cells attack the patient's body. Researchers will give ruxolitinib before, during, and after the transplant to 50 patients to see if it reduces this risk and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.